RT Journal Article
SR Electronic
T1 Evolution of synchronous bilateral breast cancers provide insights into interactions between host, tumor and immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.28.21267674
DO 10.1101/2021.12.28.21267674
A1 Hamy, Anne-Sophie
A1 Abecassis, Judith
A1 Darrigues, Lauren
A1 Laurent, Cecile
A1 Zaccarini, François
A1 Sadacca, Benjamin
A1 Delomenie, Myriam
A1 Laas, Enora
A1 Mariani, Odette
A1 Lam, Thanh
A1 Grandal, Beatriz
A1 Lae, Marick
A1 Bieche, Ivan
A1 Vacher, Sophie
A1 Pierga, Jean-Yves
A1 Brain, Etienne
A1 Vallot, Celine
A1 Hotton, Judicael
A1 Richer, Wilfrid
A1 Waterfall, Joshua
A1 Reyal, Fabien
YR 2021
UL http://medrxiv.org/content/early/2021/12/29/2021.12.28.21267674.abstract
AB Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by the same germline genetics, reproductive life factors and environmental exposures for decades. It represents an opportunity to decipher the complex interplay between host, tumor, immune system and response to neoadjuvant chemotherapy (NAC). On a cohort of 17575 BCs treated between 2005 and 2012, sBBCs (n=404) were associated with less aggressive proliferative patterns and higher rates of luminal breast cancers (BCs) when compared with unilateral BCs (n=17171). The left and right tumors were concordant for the majority of clinical and pathological features. Tumor pairs of concordant BC subtype were more frequent than pairs of discordant BC subtype, with notably a particularly high frequency of pairs of luminal BCs. Intriguingly, both the levels of tumor infiltrating lymphocytes (TILs) and the response to NAC were modified by the subtype of the contralateral tumors. Whole exome sequencing and RNAseq analyses revealed that left and right tumors were independent from a somatic mutation and transcriptomic point of view, while primary tumors (PT) before NAC and specimens with residual disease (RD) after NAC were more closely related. The analysis of the TCR repertoire identified very little overlap between patients, while common clones were shared in bilateral tumors within each patient. After NAC, the TCR repertoire of RD was enriched and expanded with clones edited by the contralateral PT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Breast Cancer Study Group and by the Institutional Review Board of Institut Curie and was conducted in accordance with institutional and ethical rules regarding research on tissue specimens and patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors